The U.S. IPO calendar stands empty for the week ahead, the first complete void since mid-January, as two biotech pricings—City Therapeutics and Iambic—close out a thin cycle and institutional desks shift attention to a substantially larger allocation event now entering the pre-marketing phase.
City Therapeutics and Iambic priced during the prior week, both sub-$100M shelf offerings characteristic of venture-backed biotech bridge financings. Neither moved secondary volume past $15M daily in the three sessions post-pricing. The calendar silence that follows is not seasonal fatigue but positional clearing: no mandates filed, no roadshow calendars circulated, no bookrunner syndicates announced. The infrastructure is idle because the next mandate will not fit inside the current allocation architecture.
The phrase "mega IPO potentially comes into view" signals a filing expected to exceed $10B in gross proceeds, a threshold crossed only twice in U.S. equity markets since 2021. That bracket requires 45–60 days from confidential filing to pricing, meaning a April or early May launch window if documents move to the SEC this week. The identity remains unconfirmed in public filings, but three candidates meet the valuation and liquidity profile: a payments infrastructure platform last privately valued near $95B, a defense-tech contractor with $4.2B trailing revenue, and a data-center REIT carve-out holding $18B in hard assets. All three have retained bulge-bracket syndicates in the past 90 days.
The operational reality for allocators: a $10B+ IPO absorbs $30B–$40B in institutional demand during bookbuilding, pulls forward $12B–$18B in hedge fund leverage, and resets sector comps across 200–300 private portfolio marks within 72 hours of pricing. The clearing of smaller mandates is not coincidence but syndicate discipline—no bookrunner schedules a $60M biotech deal inside the shadow of a $10B allocation event. The last comparable void occurred in September 2024, 11 days before a $8.7B consumer platform priced and drew $41B in indications.
Allocators should track three events in the next 21 days: a Form S-1 amendment moving from confidential to public status, any bookrunner analyst initiating coverage on a newly public biotech from prior weeks (signals freed capacity), and term-sheet language in private secondary markets for the three named candidates. The delta between private marks and proposed IPO range will clarify whether this is a liquidity exit or a valuation reset.
The calendar is not waiting. It is loading.